About this trial
The reduction in the number of fractions in radiotherapy is especially attractive in several senses, and even more so considering breast cancer, which has a high incidence and generally favorable prognosis. Thus, as a reference Institution, the investigators intend to start the treatment of selected patients with a radiotherapy scheme of 26 Gy / 5 fractions in one week, in a controlled manner, through this project.The investigators consider the moment extremely propitious to start the study, as in addition to having the first publication of a large randomized study, proving the effectiveness and safety of the strategy, the investigators will be able to benefit more patients and the health system itself by minimizing the daily visits of these patients at the hospital.
Eligibility criteria
Qualifiers
Information to the patient and signed informed consent;
Women aged ≥18 years;
Breast conserving surgery;
Invasive adenocarcinoma (except classic invasive lobular carcinoma);
Disqualifiers
Previous local irradiation;
Concomitant chemotherapy. Concomitance with trastuzumab or hormone blockade will be allowed;
Histology of metaplastic carcinoma;
History of another neoplasm: non-melanoma skin cancer, carcinoma in situ of the uterine cervix. Another neoplasm treated with curative intent and without evidence of disease in the last 5 years will be allowed.
Trial design
Treatments tested in this trial
- Ultra-hypofractionated whole breast radiotherapy
- Standard Radiation